Trial Profile
Nab-paclitaxel + gemcitabine as first-line treatment in advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.